Ironwood Pharmaceuticals Inc. [NASDAQ: IRWD] stock went on a downward path that fall over -0.35% on Wednesday, amounting to a one-week price decrease of less than -1.30%. The company report on January 9, 2023 that Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance.
– sNDA submitted to U.S. FDA in December 2022 seeking approval of a new indication of LINZESS® (linaclotide) for functional constipation in children and adolescents 6 to 17 years of age –.
– Expects high single-digit LINZESS® EUTRx prescription demand growth in 2023 –.
Over the last 12 months, IRWD stock dropped by -2.99%. The one-year Ironwood Pharmaceuticals Inc. stock forecast points to a potential upside of 12.54. The average equity rating for IRWD stock is currently 2.30, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.76 billion, with 153.07 million shares outstanding and 150.89 million shares in the current float. Compared to the average trading volume of 1.82M shares, IRWD stock reached a trading volume of 4702756 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Ironwood Pharmaceuticals Inc. [IRWD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IRWD shares is $13.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IRWD stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
CapitalOne have made an estimate for Ironwood Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 02, 2022. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on April 22, 2022, representing the official price target for Ironwood Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $14 to $9, while Wells Fargo kept a Equal Weight rating on IRWD stock.
The Average True Range (ATR) for Ironwood Pharmaceuticals Inc. is set at 0.37, with the Price to Sales ratio for IRWD stock in the period of the last 12 months amounting to 4.19. The Price to Book ratio for the last quarter was 2.95, with the Price to Cash per share for the same quarter was set at 3.71. Price to Free Cash Flow for IRWD in the course of the last twelve months was 6.80 with Quick ratio for the last quarter at 25.80.
IRWD Stock Performance Analysis:
Ironwood Pharmaceuticals Inc. [IRWD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.30. With this latest performance, IRWD shares dropped by -5.64% in over the last four-week period, additionally sinking by -2.90% over the last 6 months – not to mention a drop of -2.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IRWD stock in for the last two-week period is set at 42.01, with the RSI for the last a single of trading hit 39.13, and the three-weeks RSI is set at 44.65 for Ironwood Pharmaceuticals Inc. [IRWD]. The present Moving Average for the last 50 days of trading for this stock 11.85, while it was recorded at 11.46 for the last single week of trading, and 11.50 for the last 200 days.
Insight into Ironwood Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Ironwood Pharmaceuticals Inc. [IRWD] shares currently have an operating margin of +56.12 and a Gross Margin at +99.63. Ironwood Pharmaceuticals Inc.’s Net Margin is presently recorded at +127.72.
Return on Equity for this stock inclined to 158.09, with Return on Assets sitting at 62.68.
Ironwood Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.80 and a Current Ratio set at 25.80.
Ironwood Pharmaceuticals Inc. [IRWD] Insider Position Details
There are presently around $1,926 million, in the hands of institutional investors. The top three institutional holders of IRWD stocks are: BLACKROCK INC. with ownership of 24,970,098, which is approximately -7.141% of the company’s market cap and around 1.40% of the total institutional ownership; SARISSA CAPITAL MANAGEMENT LP, holding 16,390,000 shares of the stock with an approximate value of $186.35 million in IRWD stocks shares; and VANGUARD GROUP INC, currently with $164.69 million in IRWD stock with ownership of nearly 0.033% of the company’s market capitalization.
Positions in Ironwood Pharmaceuticals Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 123 institutional holders increased their position in Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] by around 15,501,324 shares. Additionally, 119 investors decreased positions by around 21,386,813 shares, while 39 investors held positions by with 132,463,926 shares. The mentioned changes placed institutional holdings at 169,352,063 shares, according to the latest SEC report filing. IRWD stock had 34 new institutional investments in for a total of 3,327,539 shares, while 31 institutional investors sold positions of 1,575,588 shares during the same period.